Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Eliane Nguyen, MD, Natasha Szuber, MD, Michael Harnois, Lambert Busque, MD, Luigina Mollica, MD FRCPC, PhD, Sarit E Assouline, MD MSc, Ines Chamakhi, MD MD FRCP(C), Harold J. Olney, MD, Shireen Sirhan, MD

Blood (2020) 136 (Supplement 1): 4–7.

https://doi.org/10.1182/blood-2020-141835

Published: 2020

Journal Articles

Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Reddy Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2018-99-117540

Published: 2018

Journal Articles

Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates

Natasha Szuber, MD, Sravanthi Lavu, MBBS, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2018-99-109721

Published: 2018

Journal Articles

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Kebede H. Begna, MD, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Mrinal M. Patnaik, MD MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Shireen Sirhan, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Lambert Busque, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2018-99-109740

Published: 2018

Journal Articles

MPL -Mutated Essential Thrombocythemia: A Morphologic Reappraisal

Natasha Szuber, MD, Curtis A. Hanson, MD, Terra L. Lasho, PhD, Christy Finke, BS, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2018-99-115272

Published: 2018

Journal Articles

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Paola Guglielmelli, MD PhD, Naseema Gangat, MBBS, Giacomo Coltro, MD, Terra L. Lasho, PhD, Giuseppe Gaetano Loscocco, MD, Christy Finke, BS, Benedetta Sordi, MD, Mythri Mudireddy, MBBS, Giada Rotunno, PhD, Natasha Szuber, MD, Annalisa Pacilli, PhD, Rangit Reddy Vallapureddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2018-99-110045

Published: 2018

Journal Articles

Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events

Rangit Reddy Vallapureddy, MBBS, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Domenico Penna, MD, Maura Nicolosi, MD, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Kebede H. Begna, MD, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2018-99-109895

Published: 2018

Journal Articles

The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis

Ayalew Tefferi, MD, Terra L. Lasho, PhD, Christy Finke, BS, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Reddy Vallapureddy, MBBS, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2018-99-110046

Published: 2018

Journal Articles

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Ayalew Tefferi, MD, Natasha Szuber, MD, Kebede H. Begna, MD, Mrinal M. Patnaik, MD MBBS, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS

Blood (2018) 132 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2018-99-116601

Published: 2018

Journal Articles

Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies

Maura Nicolosi, MD, Domenico Penna, MD, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Rhett P. Ketterling, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2018-99-109714

Published: 2018

Journal Articles

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

Domenico Penna, MD, Natasha Szuber, MD, Terra L. Lasho, PhD, Christy Finke, BS, Rangit Reddy Vallapureddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2018-99-119910

Published: 2018

Journal Articles

20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients

Domenico Penna, MD, Maura Nicolosi, MD, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4301.

https://doi.org/10.1182/blood-2018-99-109718

Published: 2018

Journal Articles

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Ayalew Tefferi, MD, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giacomo Coltro, MD, Christy Finke, BS, Giuseppe Gaetano Loscocco, MD, Mythri Mudireddy, MBBS, Benedetta Sordi, MD, Natasha Szuber, MD, Giada Rotunno, PhD, Rangit Vallapureddy, MBBS, Annalisa Pacilli, PhD, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 578.

https://doi.org/10.1182/blood-2018-99-109715

Published: 2018

Journal Articles

Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis

Natasha Szuber, MD, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2018-99-117458

Published: 2018

NARROW

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger

Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

MPL -Mutated Essential Thrombocythemia: A Morphologic Reappraisal

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events

The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only